AstraZeneca: Imfinzi Granted US Orphan Drug Designation
July 12 2019 - 2:46AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug
Administration had awarded its cancer drug Imfinzi orphan drug
status as a treatment for small-cell lung cancer.
The designation is given to medicines that aim to treat rare
diseases and provides benefits such as market exclusivity and
faster regulatory approvals.
Imfinzi is currently approved as a treatment for inoperable
stage 3 non-small-cell lung cancer after chemotherapy and radiation
therapy.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 12, 2019 02:31 ET (06:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024